Novartis' Narasimhan Bullish On Cosentyx Keeping Market Lead
This article was originally published in Scrip
Executive Summary
Novartis AG hopes new Phase III data showing most patients were able to maintain clear or nearly clear skin for up to three years by using Cosentyx (secukinumab) will reinforce and expand use of its new plaque psoriasis treatment.